Comparison of the Prognostic Impact of c-MET Altered Expression and the EORTC Scoring System in Non-Muscle Invasive Bladder Cancer: A PILOT STUDY

Document Type : Original Article

Authors

1 Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

2 Urology Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

Abstract

Background: Non-muscle invasive bladder cancer (NMIBC) is usually treatable especially when diagnosed early. Unfortunately, the disease has one of the highest rates of recurrence reaching up to 75 % of the cases worldwide. At present the current scoring systems involve complex calculations and imbalance of the prevalence of risk groups. The proto-oncogene c-MET encodes MET, a member of the receptor tyrosine kinases family. c-MET expression was reported to be strongly associated with bladder cancer (BC) development and prognosis. Aim: To compare the prognostic effect of c-MET and the European Organization for Research and Treatment of Cancer (EORTC)scoring systems on NMIBC disease short-term recurrence. Methods: Quantitative real-time PCR was performed in 30 NMIBC patients with pathologically confirmed diagnoses of primary tumors and 20 patients with benign bladder diseases as a control to analyze the level of c-MET expression. Short-term recurrence rates were calculated for each patient using the EORTC scoring system. Kaplan Meier and univariate analysis using the Cox regression were performed. Results: c-MET expression was upregulated in NMIBC patients with a median of (median=3.7fold) (p < 0.001). The EROTC tables overestimated the risk of short-term recurrence. The log-rank test indicated a better discrimination ability of c-MET risk stratification compared to EORTC tables with (p=0.001) and (p=0.093) respectively. Using univariate analysis c-MET expression showed association with recurrence (p=0.001). Conclusion: EORTC risk tables exhibit poor discrimination ability in predicting NMIBC recurrence. c-MET could be a promising marker for NMIBC prognosis and could be used for risk stratification after further validation of its role by larger studies

Keywords

Main Subjects

Files

Share

How to cite

Statistics